Table 2.
Baseline Characteristics of the Study Cohort
| Characteristic | Training Cohort | Validation Cohort | P Value |
|---|---|---|---|
| (n = 119) | (n = 51) | ||
| Age, mean ± SD, y | 4.82 ± 3.19 | 4.97 ± 2.56 | 0.54 |
| Gender | 0.86 | ||
| Female | 50 (42%) | 20 (39.2%) | |
| Male | 69 (58%) | 31 (60.8%) | |
| Basic disease | 0.96 | ||
| No | 103 (86.6%) | 50 (98%) | |
| Yes a | 16 (13.4%) | 6 (11.8%) | |
| Disease type | 0.76 | ||
| Severe | 63 (52.9%) | 29 (56.9%) | |
| Critical | 56 (47.1%) | 22 (43.1%) |
aPatients with 1 of the following: Chronic lung disease, cardiovascular diseases, Digestive system disease, Neuro/neuromuscular diseases, Hereditary metabolic diseases, Developmental delay/precocity, Low immune function (tumor, blood tumor disease, transplantation, HIV, etc.), mental illness, systemic lupus erythematosus, etc